BRANDON MCLAUGHLIN: Open Payments
NPI 1104935071 · CENTRAL CITY, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$574 in 38 payments from 17 companies in 2025. Trend: 2023 $277 · 2024 $347 · 2025 $574
Food & beverage: $574
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 13 | $165 |
| E.R. Squibb & Sons, L.L.C. | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Lundbeck LLC | 2 | $34 |
| Amgen Inc. | 2 | $32 |
| ABBVIE INC. | 2 | $31 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $30 |
| Novo Nordisk Inc | 2 | $30 |
| Neurocrine BioSciences, Inc. | 2 | $29 |
| Ardelyx, Inc. | 1 | $26 |
Products named: UZEDY, REXULTI, AUSTEDO XR, EVENITY, VRAYLAR, ELIQUIS, CAPLYTA, Rybelsus.
Industry payments across NE — which companies pay providers there.
